Abstract
Although travellers’ diarrhoea can sometimes be associated with postinfectious complications, the condition is typically self-limiting. The infectious-diarrhoea guidelines subcommittees of the Infectious Disease Society of America and the American College of Gastroenterology recommend empirical antibacterial therapy for travellers’ diarrhoea. Because therapy is directed largely at relieving symptoms and minimising inconvenience, the chosen antibacterial should ideally be both efficacious and pose a low risk of adverse effects.
This review discusses the safety and tolerability of rifaximin in the treatment of travellers’ diarrhoea, with a focus on data from controlled clinical trials. Data were obtained from a MEDLINE search using the key word ‘rifaximin’ with no date limits and from the rifaximin New Drug Application submitted to the US FDA for approval to market rifaximin in the US.
Currently, the antibacterials considered as standard treatment for travellers’ diarrhoea are systemically absorbed, carry defined risks of adverse effects, and have many uses other than the treatment of enteric disease. The minimally absorbed (<0.4%) oral antibacterial rifaximin constitutes a nonsystemic approach to antidiarrhoeal therapy that should overcome some of the limitations of current antibacterials used for travellers’ diarrhoea. Rifaximin is differentiated from these, and most other antibacterials, by having a tolerability profile comparable with that of placebo and minimal potential for drug interactions. To date, clinically relevant resistance to rifaximin has not been observed. As the first nonabsorbable antibacterial to be marketed for travellers’ diarrhoea, rifaximin should help to change the management paradigm for travellers’ diarrhoea and other gastrointestinal illnesses from a systemic approach to a predictably safer, nonsystemic approach.
Similar content being viewed by others
References
Hill DR. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg 2000; 62: 585–9
Steffen R, van der Linde F, Gyr K, et al. Epidemiology of diarrhea in travelers. JAMA 1983; 249: 1176–80
Gorbach SL, Carpenter C, Grayson R, et al. Consensus conference: travelers’ diarrhea. JAMA 1985; 253: 2700–4
Steffen R. Epidemiologic studies of travelers’ diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis 1986; 8Suppl. 2: S122–30
DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrhea. N Engl J Med 1993; 328: 1821–7
Peltola H, Gorbach SL. Travelers’ diarrhea: epidemiology and clinical aspects. Chapter 20.1. In DuPont HL, Steffen R, editors. Textbook of travel medicine and health. 2nd ed. Hamilton (ON): BC Decker Inc, 2001: 151–9
Ericsson CD, DuPont HL. Travelers’ diarrhea: approaches to prevention and treatment. Clin Infect Dis 1993; 16: 616–24
Rees JH, Soudain SE, Gregson NA, et al. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995; 333: 1374–9
Taylor DN, Connor BA, Shlim DR. Chronic diarrhea in the returned traveler. Med Clin North Am 1999; 83: 1033–52
Guerrant RL, Van Gilder T, Stein TS, et al. IDSA guidelines: practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32: 331–50
DuPont HL. Guidelines on acute infectious diarrhea in adults. Am J Gastroenterol 1997; 92: 1962–75
Cipro (ciprofloxacin hydrochloride) prescribing information. Bayer Corporation, 2002
Noroxin (norfloxacin) prescribing information. Merck and Company Inc, 1999
Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999; 340: 1525–32
Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341–5
Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45: 212–6
Ericsson CD. Rifaximin: a new approach to the treatment of travelers’ diarrhea. J Travel Med 2001; 8Suppl. 2: S25
Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21: 536–41
Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 51–6
DuPont HL, Ericsson CD, Mathewson JJ, et al. Oral aztreonam, a poorly absorbed, yet effective, therapy for bacterial diarrhea in US travelers to Mexico. JAMA 1992; 267: 1932–5
Ericsson CD, DuPont HL, Sullivan P, et al. Bicozamycin, a poorly absorbed antibiotic, effectively treats travelers’ diarrhea. Ann Intern Med 1983; 98: 20–5
DuPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33: 1807–15
DuPont H, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998; 59: 708–14
Sierra JM, Ruiz J, Navia MM, et al. In vitro activity of rifaximin against enteropathogens producing traveler’s diarrhea. Antimicrob Agents Chemother 2001; 45: 643–4
Salix Pharmaceuticals. Rifaximin New Drug Application, NDA 21-361. Morrisville (NC): Salix Pharmaceuticals, Inc., 2001, and Study Report CD0003.07, 12 November 2003. (Data on file)
Steffen R, Sack DA, Riopel L, et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98: 1073–8
Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers’ diarrhea. J Travel Med 2001; 8Suppl. 2: S34–9
Stornello C, Salanitri G. Controlled trial on the clinical effectiveness of the new antidiarrheal drug rifaximin. Med Praxis 1987; 8: 69–78
De Castro R, Domenichelli V, Di Lorenzo FP, et al. Rifaximin treatment for acute recurrent diarrhea in children with genitourinary disorders. Curr Ther Res 1998; 59: 746–52
Vinci M, Gatto A, Giglio A, et al. Double-blind clinical trial on infectious diarrhoea therapy: rifaximin versus placebo. Curr Ther Res 1984; 36: 92–9
Della Marchina M, Renzi G, Palazzini E. Infectious diarrhea in the aged: controlled clinical trial of rifaximin. Chemioterapia 1988; 7: 336–40
Sanfilippo A, Longo GR, Longo AR. Clinical experience with rifaximin in pediatric diarrhoeal syndromes. Med Praxis 1984; 5: 375–83
Mazzitelli M, Brega G, Dirani D, et al. Antidiarrhoeal effectiveness and tolerance in man of a local antibiotic: rifaximin. Comparative assessment using a control drug. Eur Rev Med Pharmacol Sci 1984; VI: 301–6
Palermo G, De Gregorio P, Coffa G. Effectives of the L 105 compound in the treatment of acute diarrhoeal diseases: a short-term controlled study. Med Praxis 1984; 5: 147–52
Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea. Curr Med Res Opin 1997; 14: 39–45
Beseghi U, De Angelis GL. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children. Eur Rev Med Pharmacol Sci 1998; 3-4: 131–6
Alvisi V, D’Ambrosi A, Onofri W, et al. Treatment of secretory diarrhoeas: a double-blind trial of the effectiveness of rifaximin and neomycin. Clin Trials J 1984; 21: 215–22
Fiorentino F, Simioli F, Conte M, et al. Open study on the antidiarrhoeal effectiveness of the L 105 compound. Chemoterapia 1984; III: 132–5
Ambrosioni G, Giovannini G, Lambertini A, et al. Activity and tolerance evaluation in children of a new antidiarrhoeal drug: Rifaximin. La Clinica Pediatrica 1986; 66: 1–10
Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467–84
King A, Laurie R, Connolly M, et al. The effect of rifaximin on the pharmacokinetics of single doses of intravenous and oral midazolam in healthy volunteers [abstract]. Clin Pharmacol Ther 2004; 75: P66
King A, Marshall O, Connolly M. The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estradiol and norgestimate in healthy female volunteers. Clin Pharmacol Ther 2004; 75: P96
Steffen R. The emerging role of nonabsorbable oral antibiotic therapy in the management of travelers’ diarrhea. Adv Stud Med 2003; 3: S951–8
DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 2004; 10: 1009–11
Soro O, Pesce A, Raggi M, et al. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect 1997; 3: 147–51
Acknowledgements
The author thanks Jane Saiers, PhD, for assistance with writing this manuscript. Dr Saiers’ work was funded by Salix Pharmaceuticals.
Dr Charles Ericsson has served as a consultant to Salix Pharmaceuticals, which markets rifaximin in the US. Dr Ericsson did not receive funding for the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ericsson, C.D. Safety and Tolerability of the Antibacterial Rifaximin in the Treatment of Travellers’ Diarrhoea. Drug-Safety 29, 201–207 (2006). https://doi.org/10.2165/00002018-200629030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200629030-00004